Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma.

Autor: Rioja P; Department of Medical Oncology, National Institute of Neoplastic Diseases, Lima, Peru. Electronic address: prioja@inen.sld.pe., Rey-Cardenas M; Department of Medical Oncology, Gustave Roussy, Paris Saclay University, Villejuif, France., De Velasco G; Department of Medical Oncology, University Hospital 12 de Octubre, Instituto de investigación (imas12), Madrid, Spain.
Jazyk: angličtina
Zdroj: Cancer treatment reviews [Cancer Treat Rev] 2024 Sep; Vol. 129, pp. 102801. Date of Electronic Publication: 2024 Jul 17.
DOI: 10.1016/j.ctrv.2024.102801
Abstrakt: Renal cell carcinoma (RCC) is a heterogenous disease which the incidence is increasing worldwide. The identification and understanding of the role of the Von Hipple Lindau (VHP) in regulating the hypoxia-inducible factor signaling pathway has revolutionized the treatment of this disease. Belzutifan is an oral hypoxia-inducible factor (HIF)-2α inhibitor, which has demonstrated efficacy in treating von Hippel-Lindau (VHL) disease and for the treatment of adults with RCC who experienced disease progression after PD-1/PD-L1- and VEGFR-targeted therapies. One of the most common adverse effect of this drug is anemia; however, it is treatment is not well known. This review summarizes role of the VHL-HIF pathway in ccRCC aroused the interest of targeting HIF activity, the history of belzutifan development and their relationship to anemia as well as propose a management algorithm.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: